Supernus Announces Second Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Supernus Pharma (SUPN) Tops Q2 EPS by 5c
August 2, 2016 4:34 PM EDTSupernus Pharma (NASDAQ: SUPN) reported Q2 EPS of $0.18, $0.05 better than the analyst estimate of $0.13. Revenue for the quarter came in at $50.4 million versus the consensus estimate of $49.67 million.
GUIDANCE:
Supernus Pharma sees FY2016 revenue of $200-210 million, versus the consensus of... More
